SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc....
Allows 3rd Party Applications to Directly access SugarBEAT® CGM Data Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) —...
Final step required prior to filing de novo application to the U.S. Food and Drug Administration Loughborough, England ,...
Enhances Product Capabilities in Advance of CE Mark Approval April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a...
Announces SugarBEAT® Awaiting CE Mark Approval; On Track for FDA submission in Q2 2019 Loughborough, England, March 28, 2019...
Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) — Loughborough, England – March 12, 2019 – Nemaura Medical, Inc....
Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as...
Dr. Schaebsdau to Advance European Launch of SugarBEAT® Continuous Glucose Monitor Nemaura Preparing U.S. FDA 510(k) Submission ...
Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the...
Loughborough, England –Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as...